CRISPR Therapeutics Presents Positive Data on Allogeneic … – Nasdaq
|
CRISPR Therapeutics Presents Positive Data on Allogeneic …
Nasdaq Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors-. -New data demonstrate high editing. |
